Advanced drug delivery reviews最新文献

{"title":"Immunotherapies for locally aggressive cancers","authors":"Sarah C. Adams ,&nbsp;Arun K. Nambiar ,&nbsp;Eric M. Bressler ,&nbsp;Chandrajit P. Raut ,&nbsp;Yolonda L. Colson ,&nbsp;Wilson W. Wong ,&nbsp;Mark W. Grinstaff","doi":"10.1016/j.addr.2024.115331","DOIUrl":"10.1016/j.addr.2024.115331","url":null,"abstract":"<div><p>Improving surgical resection outcomes for locally aggressive tumors is key to inducing durable locoregional disease control and preventing progression to metastatic disease. Macroscopically complete resection of the tumor is the standard of care for many cancers, including breast, ovarian, lung, sarcoma, and mesothelioma. Advancements in cancer diagnostics are increasing the number of surgically eligible cases through early detection. Thus, a unique opportunity arises to improve patient outcomes with decreased recurrence rates via intraoperative delivery treatments using local drug delivery strategies after the tumor has been resected. Of the current systemic treatments (e.g., chemotherapy, targeted therapies, and immunotherapies), immunotherapies are the latest approach to offer significant benefits. Intraoperative strategies benefit from direct access to the tumor microenvironment which improves drug uptake to the tumor and simultaneously minimizes the risk of drug entering healthy tissues thereby resulting in fewer or less toxic adverse events. We review the current state of immunotherapy development and discuss the opportunities that intraoperative treatment provides. We conclude by summarizing progress in current research, identifying areas for exploration, and discussing future prospects in sustained remission.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"210 ","pages":"Article 115331"},"PeriodicalIF":16.1,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140903767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From cells to subcellular organelles: Next-generation cancer therapy based on peptide self-assembly","authors":"Huayang Liu,&nbsp;Huaimin Wang","doi":"10.1016/j.addr.2024.115327","DOIUrl":"https://doi.org/10.1016/j.addr.2024.115327","url":null,"abstract":"<div><p>Due to the editability, functionality, and excellent biocompatibility of peptides, in situ self-assembly of peptides in cells is a powerful strategy for biomedical applications. Subcellular organelle targeting of peptides assemblies enables more precise drug delivery, enhances selectivity to disease cells, and mitigates drug resistance, providing an effective strategy for disease diagnosis and therapy. This reviewer first introduces the triggering conditions, morphological changes, and intracellular locations of self-assembling peptides. Then, the functions of peptide assemblies are summarized, followed by a comprehensive understanding of the interactions between peptide assemblies and subcellular organelles. Finally, we provide a brief outlook and the remaining challenges in this field.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115327"},"PeriodicalIF":16.1,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140844071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Advanced strategies to bridge the gap between inflammation and tissue regeneration","authors":"Márcia T. Rodrigues,&nbsp;Manuela E. Gomes","doi":"10.1016/j.addr.2024.115328","DOIUrl":"10.1016/j.addr.2024.115328","url":null,"abstract":"","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115328"},"PeriodicalIF":16.1,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-acting transdermal drug delivery formulations: Current developments and innovative pharmaceutical approaches","authors":"Tanvi Karve ,&nbsp;Amruta Dandekar ,&nbsp;Vivek Agrahari ,&nbsp;M. Melissa Peet ,&nbsp;Ajay K. Banga ,&nbsp;Gustavo F. Doncel","doi":"10.1016/j.addr.2024.115326","DOIUrl":"10.1016/j.addr.2024.115326","url":null,"abstract":"<div><p>Transdermal administration remains an active research and development area as an alternative route for long-acting drug delivery. It avoids major drawbacks of conventional oral (gastrointestinal side effects, low drug bioavailability, and need for multiple dosing) or parenteral routes (invasiveness, pain, and psychological stress and bio-hazardous waste generated from needles), thereby increasing patient appeal and compliance. This review focuses on the current state of long-acting transdermal drug delivery, including adhesive patches, microneedles, and molecularly imprinted polymeric systems. Each subsection describes an approach including key considerations in formulation development, design, and process parameters with schematics. An overview of commercially available conventional (adhesive) patches for long-acting drug delivery (longer than 24 h), the reservoir- and matrix-type systems under preclinical evaluation, as well as the advanced transdermal formulations, such as the core-shell, nanoformulations-incorporated and stimuli-responsive microneedles, and 3D-printed and molecularly imprinted polymers that are in development, is also provided. Finally, we elaborated on translational aspects, challenges in patch formulation development, and future directions for the clinical advancement of new long-acting transdermal products.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"210 ","pages":"Article 115326"},"PeriodicalIF":16.1,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24001480/pdfft?md5=3caada20d88fd6a0d6807ce782718dbd&pid=1-s2.0-S0169409X24001480-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances and strategies for nanocarrier-mediated topical therapy and theranostic for posterior eye disease","authors":"Maria João Faria ,&nbsp;José M. González-Méijome ,&nbsp;M. Elisabete C.D. Real Oliveira ,&nbsp;Gonzalo Carracedo ,&nbsp;Marlene Lúcio","doi":"10.1016/j.addr.2024.115321","DOIUrl":"10.1016/j.addr.2024.115321","url":null,"abstract":"<div><p>Posterior eye disorders, such as age-related macular degeneration, diabetic retinopathy, and glaucoma, have a significant impact on human quality of life and are the primary cause of age-related retinal diseases among adults. There is a pressing need for innovative topical approaches to treat posterior eye disorders, as current methods often rely on invasive procedures with inherent risks. Limited success was attained in the realm of topical ophthalmic delivery through non-invasive means. Additionally, there exists a dearth of literature that delves into the potential of this approach for drug delivery and theranostic purposes, or that offers comprehensive design strategies for nanocarrier developers to surmount the significant physiological ocular barriers.</p><p>This review offers a thorough and up-to-date state-of-the-art overview of 40 studies on therapeutic loaded nanocarriers and theranostic devices that, to the best of our knowledge, represent all successful works that reached posterior eye segments through a topical non-invasive administration. Most importantly, based on the successful literature studies, this review provides a comprehensive summary of the potential design strategies that can be implemented during nanocarrier development to overcome each ocular barrier.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"210 ","pages":"Article 115321"},"PeriodicalIF":16.1,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24001431/pdfft?md5=97bbb37854e77355b38af605c58d3873&pid=1-s2.0-S0169409X24001431-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design","authors":"Jennifer Stevenson ,&nbsp;Rachel Poker ,&nbsp;Johanna Schoss ,&nbsp;Michael Campbell ,&nbsp;Claire Everitt ,&nbsp;Brian Holly ,&nbsp;Nicholas Stones ,&nbsp;Ronald J. Pettis ,&nbsp;Manuel Sanchez-Felix","doi":"10.1016/j.addr.2024.115322","DOIUrl":"10.1016/j.addr.2024.115322","url":null,"abstract":"<div><p>Subcutaneous (SC) drug delivery can be a safe, effective alternative to the traditional intravenous route of administration, potentially offering notable advantages for both patients and healthcare providers. The SC Drug Development &amp; Delivery Consortium convened in 2018 to raise awareness of industry challenges to advance the development of patient-centric SC drug delivery strategies. The SC Consortium identified better understanding of patient preferences and perspectives as necessary to optimize SC product design attributes and help guide design decisions during SC product development. This manuscript provides a comprehensive overview of patient-centric factors for consideration in the SC drug delivery design and development process with the aim of establishing a foundation of existing knowledge for patient experiences related to SC drug delivery. This overview is informed by the outcomes of a multi-step survey of Consortium members and key pharmaceutical stakeholders. Framed in the context of the patient’s treatment journey, the survey findings offer future perspectives to fill data gaps to advance patient-centric SC drug delivery.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115322"},"PeriodicalIF":16.1,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140846708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin","authors":"Shrey A. Shah ,&nbsp;Robert S. Oakes ,&nbsp;Christopher M. Jewell","doi":"10.1016/j.addr.2024.115315","DOIUrl":"10.1016/j.addr.2024.115315","url":null,"abstract":"<div><p>Immunotherapies have been transformative in many areas, including cancer treatments, allergies, and autoimmune diseases. However, significant challenges persist in extending the reach of these technologies to new indications and patients. Some of the major hurdles include narrow applicability to patient groups, transient efficacy, high cost burdens, poor immunogenicity, and side effects or off-target toxicity that results from lack of disease-specificity and inefficient delivery. Thus, there is a significant need for strategies that control immune responses generated by immunotherapies while targeting infection, cancer, allergy, and autoimmunity. Being the outermost barrier of the body and the first line of host defense, the skin presents a unique immunological interface to achieve these goals. The skin contains a high concentration of specialized immune cells, such as antigen-presenting cells and tissue-resident memory T cells. These cells feature diverse and potent combinations of immune receptors, providing access to cellular and molecular level control to modulate immune responses. Thus, skin provides accessible tissue, cellular, and molecular level controls that can be harnessed to improve immunotherapies. Biomaterial platforms – microneedles, nano- and micro-particles, scaffolds, and other technologies – are uniquely capable of modulating the specialized immunological niche in skin by targeting these distinct biological levels of control. This review highlights recent pre-clinical and clinical advances in biomaterial-based approaches to target and modulate immune signaling in the skin at the tissue, cellular, and molecular levels for immunotherapeutic applications. We begin by discussing skin cytoarchitecture and resident immune cells to establish the biological rationale for skin-targeting immunotherapies. This is followed by a critical presentation of biomaterial-based pre-clinical and clinical studies aimed at controlling the immune response in the skin for immunotherapy and therapeutic vaccine applications in cancer, allergy, and autoimmunity.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115315"},"PeriodicalIF":16.1,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140794657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in local drug delivery technologies for improved rheumatoid arthritis therapy","authors":"Xiaoran An ,&nbsp;Jiapei Yang ,&nbsp;Xiaolin Cui ,&nbsp;Jiaxuan Zhao ,&nbsp;Chenwei Jiang ,&nbsp;Minglu Tang ,&nbsp;Yabing Dong ,&nbsp;Longfei Lin ,&nbsp;Hui Li ,&nbsp;Feihu Wang","doi":"10.1016/j.addr.2024.115325","DOIUrl":"https://doi.org/10.1016/j.addr.2024.115325","url":null,"abstract":"<div><p>Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by an inflammatory microenvironment and cartilage erosion within the joint cavity. Currently, antirheumatic agents yield significant outcomes in RA treatment. However, their systemic administration is limited by inadequate drug retention in lesion areas and non-specific tissue distribution, reducing efficacy and increasing risks such as infection due to systemic immunosuppression. Development in local drug delivery technologies, such as nanostructure-based and scaffold-assisted delivery platforms, facilitate enhanced drug accumulation at the target site, controlled drug release, extended duration of the drug action, reduced both dosage and administration frequency, and ultimately improve therapeutic outcomes with minimized damage to healthy tissues. In this review, we introduced pathogenesis and clinically used therapeutic agents for RA, comprehensively summarized locally administered nanostructure-based and scaffold-assisted drug delivery systems, aiming at improving the therapeutic efficiency of RA by alleviating the inflammatory response, preventing bone erosion and promoting cartilage regeneration. In addition, the challenges and future prospects of local delivery for clinical translation in RA are discussed.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115325"},"PeriodicalIF":16.1,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140647314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanomedicine biointeractions during body trafficking","authors":"Wei He,&nbsp;Huile Gao,&nbsp;Wei Wu","doi":"10.1016/j.addr.2024.115324","DOIUrl":"10.1016/j.addr.2024.115324","url":null,"abstract":"","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115324"},"PeriodicalIF":16.1,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140758213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticle-neutrophils interactions for autoimmune regulation","authors":"Daniel Kupor ,&nbsp;Michael L. Felder ,&nbsp;Shivanie Kodikalla ,&nbsp;Xueqi Chu ,&nbsp;Omolola Eniola-Adefeso","doi":"10.1016/j.addr.2024.115316","DOIUrl":"10.1016/j.addr.2024.115316","url":null,"abstract":"<div><p>Neutrophils play an essential role as ‘first responders’ in the immune response, necessitating many immune-modulating capabilities. Chronic, unresolved inflammation is heavily implicated in the progression and tissue-degrading effects of autoimmune disease. Neutrophils modulate disease pathogenesis by interacting with the inflammatory and autoreactive cells through effector functions, including signaling, degranulation, and neutrophil extracellular traps (NETs) release. Since the current gold standard systemic glucocorticoid administration has many drawbacks and side effects, targeting neutrophils in autoimmunity provides a new approach to developing therapeutics. Nanoparticles enable targeting of specific cell types and controlled release of a loaded drug cargo. Thus, leveraging nanoparticle properties and interactions with neutrophils provides an exciting new direction toward novel therapies for autoimmune diseases. Additionally, recent work has utilized neutrophil properties to design novel targeted particles for delivery into previously inaccessible areas. Here, we outline nanoparticle-based strategies to modulate neutrophil activity in autoimmunity, including various nanoparticle formulations and neutrophil-derived targeting.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"209 ","pages":"Article 115316"},"PeriodicalIF":16.1,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24001388/pdfft?md5=50a6781c275a19b6f0113c078a9a4029&pid=1-s2.0-S0169409X24001388-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140766767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}